AT 300 - Akashi Therapeutics/State University of New York at Buffalo

Drug Profile

AT 300 - Akashi Therapeutics/State University of New York at Buffalo

Alternative Names: AT-300; GsMtx-4

Latest Information Update: 28 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator State University of New York
  • Class Antiarrhythmics; Peptides
  • Mechanism of Action Calcium channel antagonists; Ion channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Atrial fibrillation; Duchenne muscular dystrophy

Most Recent Events

  • 28 Oct 2018 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA
  • 15 Sep 2014 Akashi Therapeutics licenses global development and commercialisation rights for GsMtx 4 for Duchenne muscular dystrophy
  • 15 Sep 2014 Preclinical trials in Duchenne muscular dystrophy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top